As I understand it, IMU is not funding the PD1-Vaxx PH2 “Neo-POLEM” trial.
I think a few people have misinterpreted deprioritised as shelving, which hasn’t happened (yet). Instead, they’ve wound back their financial commitment to both PD1-Vaxx and HER-Vaxx. PD1-Vaxx because someone else is funding the Ph2 and HER-Vaxx because Ph2(combo) is almost complete and almost certainly the only way to progress it further is to licence(or sell) it out to someone else, due to the cost/risk ratio and higher likelihood of commercial success offered by the CF33 based platforms and Azer-cel.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)